Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin-based regimens in metastatic colorectal cancer
NCT00114946Phase 4Terminated
- Sponsor
- Genentech
- Start
- May 2005
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Genentech. Primary endpoint: Progression-Free Survival. Started May 2005; status: terminated.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00114946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114946.